4569 — Kyorin Pharmaceutical Share News
0.000.00%
Last trade - 00:00- ¥65bn
- ¥71bn
- ¥126bn
Table: Kyorin Pharmaceutical -2025/26 group results
Table: Kyorin Pharmaceutical -2025/26 parent results
Kyorin Enters Into License Agreement With Biodol For Novel Neuropathic Pain Treatment
Table: Kyorin Pharmaceutical - 9-MTH group results
Table: Kyorin Pharmaceutical - 6-MTH group results
Kyorin And Hinge Bio Enter Into A Collaboration And License Agreement Of Hb2198 In Japan For Sle And Other Diseases
Announce Phase 3 Clinical Trial Results For Interstitial Lung Disease Drug Krp-R120
Table: Kyorin Pharmaceutical -Q1 group results
Table: Kyorin Pharmaceutical -2024/25 parent results
Table: Kyorin Pharmaceutical -2024/25 group results
Brief: Kyorin Pharmaceutical Co Ltd Says It Will Retire Treasury Shares Worth 7.2% Of Outstanding Stock On May 30
Table: Kyorin Pharmaceutical -2024/25 group forecast
Kyorin And Novartis Enter Into A Global License Agreement For Krp-M223
Table: Kyorin Pharmaceutical - 9-MTH group results
Kyorin And Bayer Enter Into License Agreement For Novel Obstructive Sleep Apnea (Osa) Treatment
Table: Kyorin Pharmaceutical -Q1 group results
Table: Kyorin Pharmaceutical -2023/24 parent results
Table: Kyorin Pharmaceutical -2023/24 group results
Table: Kyorin Pharmaceutical - 9-MTH group results